| 產品名稱 |
FHCR-1-2813/FDC-6 |
| 商品貨號 |
B164456 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Hepatoma |
| Strain |
Strain:? BALB/c (B cell); BALB/c (myeloma) |
| Applications |
The antibody reacts with human fibronectin from fetal and neoplastic tissues, but not from normal human tissues or plasma. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with SP-1 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against an onco-fetal determinant on human fibronectin |
| Cellular Products |
immunoglobulin; monoclonal antibody; against an onco-fetal determinant on human fibronectin |
| Comments |
Animals were immunized with fibronectin from HuH-6 human hepatoma cells. Spleen cells were fused with SP-1 myeloma cells. The antibody reacts with human fibronectin from fetal and neoplastic tissues, but not from normal human tissues or plasma. |
| Complete Growth Medium |
RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 0.05 mM 2-mercaptoethanol, 88%; fetal bovine serum, 12%
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation |
culture medium 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgG1 |
| Name of Depositor |
Fred Hutchinson Cancer Res. Cntr. |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Loridon-Rosa B, et al. Distribution of oncofetal fibronectin in human mammary tumors: Immunofluorescence study on histological sections. Cancer Res. 50: 1608-1612, 1990. PubMed: 2406016
Matsuura H, Hakomori S. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: Its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc. Natl. Acad. Sci. USA 82: 6517-6521, 1985. PubMed: 2995969
Matsuura H, et al. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. J. Biol. Chem. 263: 3314-3322, 1988. PubMed: 2449438
Matsuura H, Hakomori S. Monoclonal antibody defining oncofetal structure of fibronectin. US Patent 4,894,326 dated Jan 16 1990
Matsuura H, et al. An alpha-N-acetylgalactosaminylation at the threonine residue of a defined peptide sequence creates the oncofetal peptide epitope in human fibronectin. J. Biol. Chem. 264: 10472-10476, 1989. PubMed: 2471705
|
